Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Targeted Genetics initiates phase II trials for proprietary gene therapy compound

Oct. 8, 1998

Onconase and proteasome inhibitors have synergistic antitumor activity, even in resistant tumors

Oct. 8, 1998

ADIR presents two new series of ellipticine derivatives with improved profiles

Oct. 7, 1998

Antitumor agents with high potency and selectivity under evaluation at Shionogi

Oct. 6, 1998

Inex to focus internal R&D program on three cancer drug product candidates

Oct. 6, 1998

FDA approves anthracycline with orphan drug status for carcinoma in situ of the bladder

Oct. 5, 1998

Janssen terminates Avicidin agreement with NeoRx

Oct. 2, 1998

Onyx expands ONYX-015 clinical trials in pancreatic cancer

Oct. 2, 1998

Progesterone antagonists claimed for cancer, gynecological disorders by Meiji Seika

Oct. 1, 1998

Guilford, RPR amend Gliadel marketing and distribution agreement

Oct. 1, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 24, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
In the clinic for June 22, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...
K2 nabs two Antengene bispecific TCEs in $2B license, option deal
BioWorld
MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene...